Quantcast

Latest TYSABRI Stories

2008-09-19 15:00:12

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that a post-hoc analysis showed TYSABRI(R) (natalizumab) treatment increases the probability of achieving sustained improvement in physical disability over two years when compared to placebo. This post-hoc analysis provides the first evidence that TYSABRI is associated with a significant improvement in functional outcome, rather than only slowing or preventing progression of disability, in those living with relapsing...

2008-09-18 09:00:49

Biogen Idec (NASDAQ: BIIB) will present new data on the company's leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada. Nearly 20 presentations will focus on the company's products: TYSABRI(R) (natalizumab), which offers MS patients a new level of efficacy, and AVONEX(R) (Interferon beta-1a), the most prescribed MS therapy worldwide, as well as its pipeline featuring compounds targeting...

2008-09-05 06:00:23

Elan and Biogen Idec have initiated the first clinical trial of Tysabri in oncology. The first dose of Tysabri was administered earlier in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. This Phase I/II, open-label, two-arm study is designed to evaluate the safety and anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. In...

2008-09-05 03:00:06

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today announced the initiation of the first clinical trial of TYSABRI(R) (natalizumab) in oncology. The first dose of TYSABRI was administered yesterday in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of TYSABRI in patients with relapsed or refractory multiple myeloma. TYSABRI is a recombinant, humanized monoclonal antibody that targets the adhesion molecule VLA4...

2008-08-20 09:01:30

SCOTTSDALE, Ariz., Aug. 20 /PRNewswire/ -- MedPredict, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for multiple sclerosis (MS) therapies. Biogen/Elan's Tysabri has been under scrutiny due to two additional reported cases of PML, a rare and potentially fatal brain disease associated with use of the drug. MedPredict recently...

2008-07-22 03:00:18

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the two-year anniversary of TYSABRI(R) (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS), marking the reintroduction of the product in the United States (US) and the first international approval. The companies estimate that as of the end of June 2008, more than 31,800 patients worldwide are receiving TYSABRI treatment. Specifically, as of the end of June 2008: -- In the US,...

41057fcb119e40c307ac9d112e9ad5371
2008-01-15 08:59:38

The Food and Drug Administration (FDA) announced Monday it had approved Tysabri, a drug used to treat multiple sclerosis, for use in patients with moderate to severe Crohn's disease.However, the approval comes with a warning that the drug has the risk of causing a rare but serious brain infection.  Crohn's disease is a painful, serious, inflammatory bowel disease that afflicts over half a million people in the United States.   There is no known cure, and the disease typically...

2006-06-05 16:35:00

By Susan Heavey WASHINGTON (Reuters) - U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease. Three patients taking the drug, made by Biogen Idec Inc. and distributed by Elan Corp., had developed progressive multifocal leukoencephalopathy (PML). Two of them died. Food and Drug Administration officials, who faced calls from...

2006-06-05 13:03:11

WASHINGTON (Reuters) - Biogen Idec Inc. and Elan Corp. won permission on Monday to resume sales of their multiple sclerosis drug Tysabri, which was withdrawn last year after it was linked to a rare but potentially fatal brain disease, U.S. regulators said. The U.S. Food and Drug Administration said Tysabri must be sold under a restricted distribution plan to minimize chances of harm. Tysabri should be used as a stand-alone treatment and not with other drugs that suppress the immune...

2006-04-07 03:51:55

By Michael Smith DUBLIN (Reuters) - Elan Corp. Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri showed significant positive results in patients, sending its shares higher. "The Tysabri study data show not only significant reductions in relapses and disability, but also suggest improved quality of life. This is very encouraging," the company said in a statement. Elan and drugmaker Biogen Idec faced a fresh delay in getting Tysabri back to the market last...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related